Leishmania infantum: Canine Visceral Leishmaniasis – Sandfly Transmission, Zoonosis, and Diagnosis

Etiology and Taxonomic Classification

Leishmania infantum (syn. Leishmania chagasi in the New World) is a protozoan parasite belonging to the order Kinetoplastida, family Trypanosomatidae. The parasite exists in two principal morphological forms: the promastigote, a flagellated, motile form found in the alimentary tract of the sandfly vector, and the amastigote, a non-flagellated, intracellular form that resides within macrophages and other reticuloendothelial cells of the mammalian host. The kinetoplast, a specialized mitochondrial DNA structure, is a distinguishing feature of this order and serves as a target for molecular diagnostics.

Leishmania infantum is the primary etiological agent of canine visceral leishmaniasis (CVL) in the Mediterranean Basin, Latin America, the Middle East, and parts of Asia. The parasite is also the causative agent of zoonotic visceral leishmaniasis in humans, with dogs serving as the principal reservoir host. The organism is transmitted exclusively by the bite of infected female phlebotomine sandflies of the genus Phlebotomus in the Old World and Lutzomyia in the New World.

Sandfly Transmission and Vector Biology

The transmission cycle of Leishmania infantum is strictly dependent on the sandfly vector. Female sandflies require a blood meal for oogenesis and become infected when they ingest amastigote-laden macrophages from an infected canine host. Within the sandfly midgut, amastigotes transform into promastigotes, which undergo a complex developmental cycle involving several morphological stages: procyclic promastigotes, nectomonad promastigotes, leptomonad promastigotes, and finally metacyclic promastigotes. The metacyclic form is the infective stage, characterized by a highly motile, slender morphology and resistance to complement-mediated lysis.

Metacyclic promastigotes migrate to the sandfly proboscis and are inoculated into the dermis of a new host during subsequent blood feeding. The injection of saliva, which contains vasodilatory and immunomodulatory molecules, facilitates parasite deposition and establishment. Sandfly saliva contains maxadilan, a potent vasodilator, and several salivary proteins that inhibit macrophage activation and promote a Th2-biased immune response, thereby enhancing parasite survival.

The extrinsic incubation period within the sandfly ranges from 4 to 20 days depending on ambient temperature and humidity. Sandflies are crepuscular and nocturnal feeders, with peak activity occurring at dusk and dawn. Their flight range is limited, typically less than 1 kilometer, but passive transport via wind or human activity can extend dispersal distances. Peridomestic habitats, including animal shelters, kennels, and human dwellings, provide optimal breeding sites for sandflies, which lay eggs in organic-rich soil, cracks in walls, and animal burrows.

Zoonosis and Reservoir Host Dynamics

Leishmania infantum is a zoonotic pathogen, and the domestic dog (Canis lupus familiaris) is the primary reservoir host for human infection. Infected dogs can harbor high parasite burdens in the skin, bone marrow, lymph nodes, and spleen, making them efficient sources of infection for sandfly vectors. The zoonotic risk is directly proportional to the prevalence of canine infection in a given region and the density of sandfly populations.

Asymptomatic infected dogs represent a significant challenge for disease control. These animals may have low-level parasitemia and can transmit the parasite to sandflies despite lacking clinical signs. Seropositive but clinically healthy dogs have been shown to be infectious to sandflies in xenodiagnosis studies, underscoring the importance of subclinical carriers in maintaining the transmission cycle.

Other mammalian species, including foxes, jackals, wolves, and rodents, can serve as secondary reservoirs, but their role in sustaining transmission to humans is considered minor compared to that of dogs. In South America, the crab-eating fox (Cerdocyon thous) has been implicated as a sylvatic reservoir, but the domestic dog remains the primary link to human disease.

Clinical Signs and Pathology in Dogs

Canine visceral leishmaniasis presents with a broad spectrum of clinical manifestations, ranging from subclinical infection to severe, life-threatening disease. The incubation period can vary from several months to years. Clinical signs are the result of immune complex deposition, chronic inflammation, and progressive organ dysfunction.

Dermatological Manifestations

Cutaneous lesions are among the most common and earliest signs of CVL. These include:

• Exfoliative dermatitis, particularly on the face, ears, and limbs.
• Periocular alopecia and depigmentation.
• Onychogryphosis (abnormal overgrowth and curvature of the claws).
• Ulcerative dermatitis, especially over bony prominences.
• Nodular dermatitis, which may be mistaken for neoplasia.

The dermatopathology is characterized by a granulomatous to lymphoplasmacytic perifolliculitis and dermatitis, with variable numbers of amastigotes within macrophages.

Visceral and Systemic Signs

Progressive visceral involvement leads to:

• Generalized lymphadenomegaly, most notably of the popliteal, prescapular, and submandibular lymph nodes.
• Splenomegaly and hepatomegaly.
• Weight loss and muscle atrophy, particularly of the temporal and masseter muscles.
• Anorexia and lethargy.
• Polyuria and polydipsia, often secondary to renal involvement.
• Epistaxis, which is a common and often dramatic presenting sign.

Renal Pathology

Renal disease is the leading cause of mortality in CVL. Immune complex-mediated glomerulonephritis, typically membranoproliferative or membranous, leads to proteinuria, nephrotic syndrome, and ultimately renal failure. Tubulointerstitial nephritis is also common. Proteinuria is an early and sensitive indicator of renal involvement and carries a poor prognosis when severe.

Ocular Signs

Ocular manifestations include anterior uveitis, keratoconjunctivitis sicca, blepharitis, and panophthalmitis. Uveitis is often bilateral and can lead to secondary glaucoma and blindness.

Hematological and Biochemical Abnormalities

Common laboratory findings include:

• Non-regenerative anemia, often mild to moderate.
• Thrombocytopenia, which may contribute to epistaxis.
• Hyperglobulinemia, predominantly polyclonal gammopathy due to B cell activation.
• Hypoalbuminemia, reflecting chronic inflammation and renal protein loss.
• Elevated liver enzymes (ALT, ALP) in cases of hepatic involvement.
• Azotemia in advanced renal disease.

Diagnostic Approaches

The diagnosis of Leishmania infantum infection in dogs requires a combination of clinical assessment, serological testing, and molecular or parasitological confirmation. No single test has perfect sensitivity and specificity, and a multi-modal approach is recommended.

Cytological Examination

Cytological examination of tissue aspirates or impression smears is a rapid and inexpensive method for detecting amastigotes. Samples are typically obtained from lymph nodes, bone marrow, or spleen. Amastigotes appear as round to oval bodies, 2 to 4 micrometers in diameter, with a characteristic nucleus and kinetoplast. Staining with Giemsa or Diff-Quik reveals the typical morphology. Sensitivity is variable, ranging from 30% to 90% depending on the sample type and parasite burden. Bone marrow aspirates generally yield higher sensitivity than lymph node aspirates.

Serological Testing

Serological assays detect anti-Leishmania antibodies, primarily IgG. The most commonly used methods include:

• Indirect fluorescent antibody test (IFAT): Considered a reference method, with sensitivity and specificity exceeding 90% in symptomatic dogs. Cross-reactivity with other trypanosomatids (e.g., Trypanosoma cruzi) can occur.
• Enzyme-linked immunosorbent assay (ELISA): Commercial ELISA kits using recombinant antigens (e.g., rK39, rK26) offer high specificity and are suitable for large-scale screening. The rK39 antigen is a kinesin-related protein that is highly conserved among Leishmania species.
• Direct agglutination test (DAT): A simple, low-cost assay that does not require specialized equipment. Sensitivity is comparable to IFAT, but specificity may be lower.

Serological testing is highly sensitive in clinically ill dogs but may yield false-negative results in asymptomatic or early-stage infections. Conversely, seropositivity can persist for months or years after successful treatment, complicating the distinction between active infection and past exposure.

Molecular Diagnostics

Polymerase chain reaction (PCR) assays have become the gold standard for confirming Leishmania infantum infection due to their high sensitivity and specificity. Several genetic targets are used:

• Kinetoplast DNA (kDNA) minicircles: Present in thousands of copies per cell, providing exceptional sensitivity. Real-time quantitative PCR (qPCR) targeting kDNA can detect as few as 0.01 parasites per reaction.
• Internal transcribed spacer 1 (ITS1) of ribosomal DNA: A multicopy target that allows species identification through sequencing or restriction fragment length polymorphism (RFLP) analysis.
• Small subunit ribosomal RNA (SSU rRNA): A conserved target suitable for pan-Leishmania detection.

Quantitative PCR offers the additional advantage of parasite load quantification, which correlates with disease severity and can be used to monitor treatment response. A reduction in parasite load of 2 to 3 log10 copies per milliliter of blood or per microgram of tissue DNA is considered indicative of a favorable therapeutic response.

Sample types for PCR include whole blood, bone marrow, lymph node aspirates, skin biopsies, and conjunctival swabs. Conjunctival swabs are a minimally invasive sample type with good sensitivity, particularly in dogs with ocular involvement.

Diagnostic Algorithm

The following Mermaid diagram illustrates a recommended diagnostic workflow for suspected CVL.

flowchart TD
    A[Clinical suspicion of CVL], > B{Serological screening}
    B, >|Positive| C[Confirm with qPCR]
    B, >|Negative| D[Low clinical suspicion?]
    D, >|Yes| E[Monitor and retest in 3-6 months]
    D, >|No| F[Perform qPCR on bone marrow or lymph node]
    C, >|Positive| G[Confirm CVL diagnosis]
    C, >|Negative| H[Consider other differentials]
    F, >|Positive| G
    F, >|Negative| H
    G, > I[Stage disease: renal function, proteinuria, parasite load]
    I, > J[Initiate treatment and vector control]

Treatment and Management

Treatment of CVL aims to reduce parasite burden, control clinical signs, and prevent transmission to sandflies. Complete parasitological cure is rarely achieved, and most treated dogs remain infected and potentially infectious. Treatment protocols vary by region and drug availability.

First-Line Agents

• Meglumine antimoniate: A pentavalent antimonial compound that inhibits parasite glycolysis and topoisomerase I. Administered subcutaneously at 75 to 100 mg/kg once daily for 4 to 6 weeks. Adverse effects include pain at injection sites, nephrotoxicity, and pancreatitis.
• Allopurinol: A xanthine oxidase inhibitor that is metabolized by Leishmania to a toxic nucleotide analog. Administered orally at 10 to 20 mg/kg twice daily for 6 to 12 months or longer. Allopurinol is often used in combination with meglumine antimoniate to improve efficacy and reduce relapse rates.

Alternative and Adjunctive Therapies

• Miltefosine: An alkylphosphocholine compound with activity against Leishmania. Administered orally at 2 mg/kg once daily for 28 days. Gastrointestinal side effects are common.
• Domperidone: A dopamine D2 receptor antagonist that enhances cell-mediated immunity. Used as an adjunctive immunomodulator in combination with antiparasitic drugs.
• Marbofloxacin: A fluoroquinolone antibiotic with some anti-Leishmania activity. Used in combination protocols, particularly in cases of antimonial resistance.

Monitoring and Prognosis

Regular monitoring of renal function, proteinuria, and parasite load is essential during and after treatment. Dogs with severe proteinuria or azotemia have a guarded prognosis. Relapse is common, and lifelong monitoring is recommended.

Control and Prevention

Control of CVL requires an integrated approach targeting both the vector and the reservoir host.

Vector Control

• Insecticide-impregnated collars (e.g., deltamethrin, flumethrin) reduce sandfly feeding on dogs by 80% to 90%.
• Topical spot-on formulations containing permethrin or imidacloprid provide similar protection.
• Environmental management, including removal of organic debris and application of residual insecticides to kennel walls, reduces sandfly breeding sites.

Canine Vaccination

Several vaccines against CVL are available in endemic regions. These vaccines are based on recombinant antigens or whole killed parasites and aim to reduce clinical disease severity and infectiousness. Vaccination does not prevent infection but may reduce parasite burden and transmission. Vaccinated dogs may become seropositive, complicating the interpretation of serological surveillance.

Reservoir Management

• Mass screening and culling of seropositive dogs has been implemented in some regions but is controversial due to ethical concerns and limited efficacy.
• Treatment of infected dogs with insecticidal collars reduces their infectiousness to sandflies.
• Public education campaigns promote responsible pet ownership and vector avoidance measures.

Differential Diagnoses

The clinical signs of CVL overlap with several other diseases. Key differentials include:

• Ehrlichia canis infection (see Ehrlichia canis and Monocytic Ehrlichiosis in Dogs).
• Anaplasma phagocytophilum infection (see Anaplasma phagocytophilum in Livestock and Companion Animals).
• Systemic lupus erythematosus.
• Immune-mediated hemolytic anemia.
• Lymphoma or multiple myeloma.
• Chronic renal failure from other causes.

Conclusion

Leishmania infantum remains a major cause of morbidity and mortality in dogs across endemic regions and poses a significant zoonotic threat. The complex interplay between the sandfly vector, the canine reservoir, and the human host requires a One Health approach to surveillance, diagnosis, and control. Advances in molecular diagnostics, particularly quantitative PCR, have improved the sensitivity and specificity of infection detection and allow for objective monitoring of treatment response. Integrated vector management, combined with responsible pet ownership and vaccination where available, offers the most sustainable path toward reducing the burden of this disease.

References

1. Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L. Canine leishmaniosis – new concepts and insights on an expanding zoonosis: part one. Trends in Parasitology. 2008;24(7):324-330.
2. Solano-Gallego L, Miró G, Koutinas A, Cardoso L, Pennisi MG, Ferrer L, et al. LeishVet guidelines for the practical management of canine leishmaniosis. Parasites & Vectors. 2011;4:86.
3. Palatnik-de-Sousa CB, Day MJ. One Health: the global challenge of epidemic and endemic leishmaniasis. Parasites & Vectors. 2011;4:197.
4. Otranto D, Dantas-Torres F. The prevention of canine leishmaniasis and its impact on public health. Trends in Parasitology. 2013;29(7):339-345.
5. Maia C, Campino L. Methods for diagnosis of canine leishmaniasis and immune response to infection. Veterinary Parasitology. 2008;158(4):274-287.